SELLAS Life Sciences Group, Inc.
SLS
$1.56
-$0.05-3.11%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -20.19% | 20.69% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -24.38% | 9.40% | |||
| Operating Income | 24.38% | -9.40% | |||
| Income Before Tax | 13.72% | 5.22% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 13.72% | 5.22% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 13.72% | 5.22% | |||
| EBIT | 24.38% | -9.40% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 27.33% | 12.49% | |||
| Normalized Basic EPS | 37.46% | -1.69% | |||
| EPS Diluted | 27.33% | 12.49% | |||
| Normalized Diluted EPS | 37.46% | -1.69% | |||
| Average Basic Shares Outstanding | 18.61% | 8.40% | |||
| Average Diluted Shares Outstanding | 18.61% | 8.40% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||